Atea announces presentation of Phase 1 data of bemnifosbuvir at ICAR 2023

Atea Pharmaceuticals announced the presentation of new Phase 1, in vitro and in vivo data that demonstrate key profile attributes of Atea’s lead drug candidate, bemnifosbuvir, for the treatment of COVID-19 and hepatitis C. Additionally, new data for AT-752 for dengue and a nucleotide analogue are being presented. These results are being presented at the 36th International Conference on Antiviral Research, ICAR 2023, taking place March 13-17, 2023 in Lyon, France. Key highlights of the presentations include results from a Phase 1 human absorption, distribution, metabolism, and excretion, ADME, study for bemnifosbuvir demonstrating a favorable ADME profile supportive of the dosing regimen used in SUNRISE-3, a global, multicenter Phase 3 registrational trial for the treatment of COVID-19. In vitro metabolism and transporter interaction studies showed bemnifosbuvir has a low risk for interactions with medicines commonly prescribed to patients at risk for COVID-19 progression and for those with HCV infection. In vitro studies also demonstrated advantages of bemnifosbuvir’s mechanism of action, which targets conserved regions of the viruses that cause COVID-19 and HCV infection. Additionally, the combination of bemnifosbuvir and ruzasvir for the treatment of HCV demonstrated potent in vitro synergistic antiviral activity and in vivo preclinical safety without adverse interactions. "As we continue to advance late-stage development of bemnifosbuvir, these data demonstrate that our lead compound has the potential to improve the current standard of care and address key unmet needs and limitations for patients with COVID-19 and HCV," said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. "These data support a favorable safety and drug interaction profile of bemnifosbuvir to treat these conditions and to provide vulnerable patients with another therapeutic option."